Atlas Trials

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

Clinical trial NCT06549400 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT06549400
Sponsor
Lupin Ltd.
Status
ENROLLING_BY_INVITATION
Phase
Phase 3
Study type
INTERVENTIONAL
Myotonic Dystrophy
Start date
2025-09-12
Primary completion
2028-05-29
Enrollment
176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.